DDInter1492 DDInter782
Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Ponatinib {u} (Compound) binds {v} (Gene) RET
Ponatinib {u} (Compound) upregulates {v} (Gene) RAB15
Ponatinib {u} (Compound) downregulates {v} (Gene) ATP6V0B
Ponatinib {u} (Compound) causes {v} (Side Effect) Migraine
Ponatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ranitidine
Ponatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sodium citrate
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vibrio cholerae CVD 103-HgR strain live antigen
Ponatinib {u} may lead to a major life threatening interaction when taken with {v} Ramucirumab
Ponatinib {u} may lead to a major life threatening interaction when taken with {v} Tucatinib
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Ponatinib (Compound) binds RET (Gene)
Ponatinib (Compound) upregulates RAB15 (Gene)
Ponatinib (Compound) downregulates ATP6V0B (Gene)
Ponatinib (Compound) causes Migraine (Side Effect)
Ponatinib may cause a minor interaction that can limit clinical effects when taken with Ranitidine
Ponatinib may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Ponatinib may lead to a major life threatening interaction when taken with Ramucirumab
Ponatinib may lead to a major life threatening interaction when taken with Tucatinib